Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $29.06, Implies 94% UpsideTradingView·23 hours agoSMMT-8.81%
Summit Therapeutics Flags Going Concern Risk Over Cash Needsbenzinga_article·1 day ago, 10:53 AMSMMT-8.81%
Deckers Outdoor, Summit Therapeutics, Robert Half And Other Big Stocks Moving Lower In Friday’s Pre-Market Sessionbenzinga_article·1 day ago, 07:04 AMSMMT-8.81%KRNY+3.07%
Summit Therapeutics launches at-the-market equity program for up to $380 millionPUBT·2 days ago, 03:57 PMSMMT-8.81%JPM+0.95%
SMMT: Ivonescimab advances in Phase III, but funding shortfall raises going concern riskQuartr·2 days ago, 03:13 PMSMMT-8.81%
SMMT: Ivonescimab achieved landmark Phase III survival results and FDA BLA acceptance, with strong cash reservesQuartr·2 days ago, 03:12 PMSMMT-8.81%
